T1	Participants 194 267	169 previously untreated patients with advanced epithelial ovarian cancer
T2	Participants 462 477	Eleven patients
T3	Participants 570 582	153 patients
T4	Participants 990 1012	47 complete responders
T5	Participants 1102 1114	158 patients
T6	Participants 1139 1150	90 patients
T7	Participants 1538 1549	both groups
T8	Participants 1472 1496	melphalan-platinum group
T9	Participants 681 724	6 partial responders, and 100 nonresponders
